NovoCure Limited (NASDAQ:NVCR - Free Report) - Investment analysts at Wedbush reduced their Q1 2025 EPS estimates for shares of NovoCure in a note issued to investors on Wednesday, April 16th. Wedbush analyst D. Nierengarten now expects that the medical equipment provider will post earnings of ($0.74) per share for the quarter, down from their previous estimate of ($0.71). Wedbush has a "Neutral" rating and a $27.00 price objective on the stock. The consensus estimate for NovoCure's current full-year earnings is ($1.30) per share. Wedbush also issued estimates for NovoCure's Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.74) EPS and FY2027 earnings at ($2.64) EPS.
A number of other research firms also recently weighed in on NVCR. HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of NovoCure in a report on Tuesday, January 14th. Piper Sandler reduced their price target on NovoCure from $42.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday. StockNews.com raised NovoCure from a "sell" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.83.
Get Our Latest Analysis on NVCR
NovoCure Stock Up 5.5 %
NVCR traded up $0.91 during midday trading on Friday, hitting $17.42. 395,954 shares of the company's stock traded hands, compared to its average volume of 1,179,353. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The company has a market cap of $1.91 billion, a PE ratio of -12.44 and a beta of 0.65. The stock's fifty day simple moving average is $18.73 and its 200-day simple moving average is $21.60. NovoCure has a one year low of $11.70 and a one year high of $34.13.
NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.27). The company had revenue of $161.27 million during the quarter, compared to analyst estimates of $161.30 million. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%.
Hedge Funds Weigh In On NovoCure
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of NovoCure by 1.3% during the third quarter. Geode Capital Management LLC now owns 2,405,257 shares of the medical equipment provider's stock valued at $37,601,000 after purchasing an additional 29,871 shares during the period. Tidal Investments LLC raised its stake in shares of NovoCure by 4.6% in the 3rd quarter. Tidal Investments LLC now owns 55,756 shares of the medical equipment provider's stock valued at $871,000 after buying an additional 2,465 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of NovoCure by 222.6% during the 3rd quarter. Franklin Resources Inc. now owns 180,853 shares of the medical equipment provider's stock valued at $2,904,000 after acquiring an additional 124,793 shares in the last quarter. Versant Capital Management Inc raised its position in NovoCure by 35.8% in the fourth quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider's stock worth $100,000 after purchasing an additional 880 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in NovoCure by 57.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider's stock worth $129,000 after purchasing an additional 1,575 shares during the period. 84.61% of the stock is currently owned by institutional investors.
NovoCure Company Profile
(
Get Free Report)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Recommended Stories
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
